Dyadic International (DYAI) EBT Growth (3y) (2021 - 2026)
Powered by 
Analysis
Dyadic International (DYAI) EBT Growth (3y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.85 Bn | 192.86 Bn | 7.24 Bn | 19.70% |
| 2 | Gilead Sciences | 180.09 Bn | 176.91 Bn | 6.22 Bn | -103.74% |
| 3 | Vertex Pharmaceuticals | 131.06 Bn | 123.21 Bn | 2.84 Bn | 6.22% |
| 4 | Regeneron Pharmaceuticals | 81.82 Bn | 73.82 Bn | 3.93 Bn | 12.16% |
| 5 | Argenx Se | 60.39 Bn | 55.21 Bn | 1.37 Bn | 103.79% |
| 6 | Moderna | 54.31 Bn | 49.17 Bn | 52.00 Mn | 24.03% |
| 7 | Alnylam Pharmaceuticals | 33.13 Bn | 29.82 Bn | 992.69 Mn | 38.36% |
| 8 | Biogen | 31.90 Bn | 30.62 Bn | 1.96 Bn | -42.82% |
| 9 | Roivant Sciences | 29.23 Bn | 29.23 Bn | 1.16 Mn | - |
| 10 | Dyadic International | 17.59 Mn | 9.63 Mn | - | 0.62% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 0.62% |
| Dec 31, 2025 | 10.86% |
| Sep 30, 2025 | -2.49% |
| Jun 30, 2025 | 18.66% |
| Mar 31, 2025 | 9.93% |
| Dec 31, 2024 | 28.89% |
| Sep 30, 2024 | 63.30% |
| Jun 30, 2024 | 19.68% |
| Mar 31, 2024 | 91.45% |
| Dec 31, 2023 | -2.41% |
| Sep 30, 2023 | 13.56% |
| Jun 30, 2023 | 6.30% |
| Mar 31, 2023 | 4.22% |
| Dec 31, 2022 | -7.47% |
| Sep 30, 2022 | -2.13% |
| Jun 30, 2022 | -6.84% |
| Mar 31, 2022 | -8.03% |
| Dec 31, 2021 | -40.53% |
| Sep 30, 2021 | -29.21% |
| Jun 30, 2021 | -34.05% |